ACXP vs. PGNY
ACXP (Acurx Pharmaceuticals, Inc.) and PGNY (Progyny, Inc.) are both stocks. Both are in the Healthcare sector — ACXP in Biotechnology, PGNY in Health Information Services. Over the past 3 years, ACXP returned -69.14%/yr vs -10.45%/yr for PGNY. At a 0.09 correlation, their price movements are largely independent.
Performance
ACXP vs. PGNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ACXP achieves a -39.36% return, which is significantly lower than PGNY's 2.34% return.
ACXP
- 1D
- -1.95%
- 1M
- -23.35%
- YTD
- -39.36%
- 6M
- -56.23%
- 1Y
- -86.27%
- 3Y*
- -69.14%
- 5Y*
- —
- 10Y*
- —
PGNY
- 1D
- 0.77%
- 1M
- 5.63%
- YTD
- 2.34%
- 6M
- -2.52%
- 1Y
- 25.26%
- 3Y*
- -10.45%
- 5Y*
- -15.15%
- 10Y*
- —
ACXP vs. PGNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
ACXP Acurx Pharmaceuticals, Inc. | -39.36% | -84.71% | -78.75% | -3.77% | -7.90% | -27.37% |
PGNY Progyny, Inc. | 2.34% | 48.87% | -53.60% | 19.36% | -38.13% | -15.19% |
Correlation
The correlation between ACXP and PGNY is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Jun 25, 2021 | 0.09 |
Fundamentals
ACXP:
$4.10M
PGNY:
$2.23B
ACXP:
-$959.29
PGNY:
$0.76
ACXP:
0.00
PGNY:
5.07
ACXP:
$0.00
PGNY:
$1.29B
ACXP:
$0.00
PGNY:
$311.76M
ACXP:
-$5.88M
PGNY:
$108.11M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ACXP vs. PGNY — Risk / Return Rank
ACXP
PGNY
ACXP vs. PGNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Acurx Pharmaceuticals, Inc. (ACXP) and Progyny, Inc. (PGNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ACXP | PGNY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.91 | ||
| Sortino ratioReturn per unit of downside risk | -1.93 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.16 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 0.60 | -1.56 |
| Martin ratioReturn relative to average drawdown | -1.25 | 1.27 | -2.52 |
Loading charts...
Drawdowns
ACXP vs. PGNY - Drawdown Comparison
The maximum ACXP drawdown since its inception was -99.14%, which is greater than PGNY's maximum drawdown of -79.49%. Use the drawdown chart below to compare losses from any high point for ACXP and PGNY.
Loading charts...
Drawdown Indicators
| ACXP | PGNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.14% | -79.49% | -19.65% |
Max Drawdown (1Y)Largest decline over 1 year | -89.26% | -42.65% | -46.61% |
Max Drawdown (3Y)Largest decline over 3 years | -98.83% | -68.14% | -30.69% |
Max Drawdown (5Y)Largest decline over 5 years | — | -79.49% | — |
Current DrawdownCurrent decline from peak | -99.04% | -60.58% | -38.46% |
Average DrawdownAverage peak-to-trough decline | -69.51% | -42.48% | -27.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 69.15% | 19.90% | +49.25% |
Volatility
ACXP vs. PGNY - Volatility Comparison
Acurx Pharmaceuticals, Inc. (ACXP) has a higher volatility of 12.17% compared to Progyny, Inc. (PGNY) at 8.52%. This indicates that ACXP's price experiences larger fluctuations and is considered to be riskier than PGNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ACXP | PGNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.17% | 8.52% | +3.65% |
Volatility (6M)Calculated over the trailing 6-month period | 119.74% | 41.34% | +78.40% |
Volatility (1Y)Calculated over the trailing 1-year period | 188.57% | 56.84% | +131.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 140.92% | 56.05% | +84.87% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 140.92% | 62.08% | +78.84% |
Dividends
ACXP vs. PGNY - Dividend Comparison
Neither ACXP nor PGNY has paid dividends to shareholders.
Financials
ACXP vs. PGNY - Financials Comparison
This section allows you to compare key financial metrics between Acurx Pharmaceuticals, Inc. and Progyny, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ACXP and PGNY have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ACXP has higher volatility (12.17%) compared to PGNY (8.52%). In terms of maximum drawdown, ACXP dropped -99.14% vs PGNY's -79.49%.
PGNY currently has the higher Sharpe Ratio (0.45 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ACXP and PGNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer